Overview
Share price change
24h
Current
Min
9.17
Max
9.65
Income | 64M 17M |
|---|---|
Sales | -7.7M 9.2M |
EPS | -0.2 |
Profit margin | 182.94 |
Employees | 161 |
EBITDA | -28M -71M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +631.47% upside |
Market Cap | 65M |
|---|---|
Previous open | 15.79 |
Previous close | 9.17 |
Gossamer Bio Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
9 paź 2026, 19:55 UTC
Gossamer Bio Inc shares fell sharply, continuing a notable decline since Thursday's close and remaining well below the 20-day moving average.
Read
8 paź 2026, 23:15 UTC
Gossamer Bio Inc shares advanced in after-market trading following Thursday's close, although they remain significantly below their 20-day moving average.
Read
7 paź 2026, 22:01 UTC
Gossamer Bio Inc is advancing in after-market trading, gaining notable ground since Wednesday's close despite being below its 20-day moving average.
Read
6 paź 2026, 19:45 UTC
Gossamer Bio Inc shares are higher today, having advanced since Monday's close, though they remain below their 20-day moving average.
Read
5 paź 2026, 22:01 UTC
Gossamer Bio Inc saw a significant rally in after-market trading, recovering from previous dips and closing above its 20-day moving average.
Read
2 paź 2026, 22:20 UTC
Gossamer Bio Inc is trading lower in after-hours, continuing a downward trend amid broader market declines, with three consecutive sessions finishing lower.
Read
1 paź 2026, 20:06 UTC
Gossamer Bio Inc shares fell sharply, reversing an early uptick and continuing to decline, remaining well below their 20-day moving average.
Read
28 wrz 2026, 20:07 UTC
Gossamer Bio Inc is sharply higher, recovering notably since Friday's close, despite remaining below its 20-day moving average and near its one-month range low.
Read
25 wrz 2026, 20:12 UTC
Gossamer Bio Inc declined sharply in after-market hours, marking a fifth consecutive session lower and remaining significantly below its 20-day moving average.
Read
24 wrz 2026, 19:35 UTC
Gossamer Bio Inc shares fell sharply after reaching a session high, despite submitting a New Drug Application for seralutinib to treat pulmonary arterial hypertension.
Read
23 wrz 2026, 23:15 UTC
Gossamer Bio Inc has submitted a New Drug Application for seralutinib targeting pulmonary arterial hypertension, with shares advancing in after-market trading.
Read
22 wrz 2026, 19:45 UTC
Gossamer Bio Inc is experiencing a sharp increase in its stock price, reaching a peak cumulative return before settling at a notable gain.
Read
21 wrz 2026, 21:41 UTC
Gossamer Bio Inc is rising in after-market trading, gaining ground since Monday's close, despite remaining below its 20-day moving average.
Read
18 wrz 2026, 22:11 UTC
Gossamer Bio Inc has rallied sharply in after-market trading, rebounding from earlier losses and advancing significantly since Friday's close.
Read
17 wrz 2026, 20:07 UTC
Gossamer Bio Inc. shares are sharply higher as the company appointed Greg Ciongoli to its Board of Directors, effective September 16, 2026.
Read
16 wrz 2026, 20:10 UTC
Gossamer Bio Inc's stock price is sharply higher in Wednesday's trading session, recovering from an initial dip to peak above Tuesday's close.
Read
15 wrz 2026, 21:05 UTC
Gossamer Bio Inc. shares traded lower in after-market hours, remaining below the 20-day moving average and near the lower end of their one-month range.
Read
14 wrz 2026, 20:07 UTC
Gossamer Bio Inc. shares are higher today amid broader market dynamics, despite ongoing concerns about rising crude oil prices and their inflationary effects.
Read
11 wrz 2026, 23:01 UTC
Gossamer Bio Inc. shares are higher in after-hours trading, reflecting a notable increase since Friday's close amid positive market sentiment following a narrower U.S. budget deficit.
Read
10 wrz 2026, 23:31 UTC
Gossamer Bio Inc. shares rose in after-market trading following a 1-for-80 reverse stock split, advancing from earlier levels despite broader market dynamics.
Read
9 wrz 2026, 23:53 UTC
Gossamer Bio Inc. shares are lower in after-market hours following a significant decline since Wednesday's close, despite an earlier attempt to recover.
Read
4 wrz 2026, 19:26 UTC
Gossamer Bio shares are lower today amid increased selling pressure on risk assets, influenced by strong jobs data and rising interest rate expectations.
Read
3 wrz 2026, 23:26 UTC
Gossamer Bio Inc shares are lower in after-market hours, with no specific news identified for the decline. Major indices rose amid reduced interest rate hike expectations.
Read
2 wrz 2026, 23:06 UTC
Gossamer Bio Inc. shares are higher in after-market trading, remaining above their 20-day moving average and within the one-month trading range.
Read
1 wrz 2026, 23:06 UTC
Gossamer Bio Inc. shares declined in after-market trading, influenced by rising oil prices and inflation concerns amid a broader performance below the 20-day moving average.
Read
31 sie 2026, 20:07 UTC
Gossamer Bio Inc is higher today amid broader market reactions to potential Federal Reserve interest rate hikes following remarks from Warsh at the Jackson Hole symposium.
Read
28 sie 2026, 23:06 UTC
Gossamer Bio Inc. shares are higher in after-market trading, reflecting positive momentum since Friday's close amid broader market volatility.
Read
27 sie 2026, 23:01 UTC
Gossamer Bio announced a private placement that could yield up to $250 million, with an initial $25 million expected upfront. Shares are roughly flat in after-market hours.
Read
26 sie 2026, 23:01 UTC
Gossamer Bio Inc is higher in after-market trading, reflecting broader market gains amid positive economic data on personal consumption and durable goods orders.
Read
25 sie 2026, 23:01 UTC
Gossamer Bio shares were lower in after-market hours, with no specific news identified. The broader market retreated after an initial advance amid falling crude oil prices.
Read
Peer Comparison
Price change
Gossamer Bio Inc Forecast
Price Target
By TipRanks
12 Months Forecast
Average 68.1 USD 631.47%
High 90 USD
Low 22.4 USD
Based on 5 Wall Street analysts offering 12 month price targets forGossamer Bio Inc - Dist in the last 3 months.
Rating Consensus
By TipRanks
Neutral
5 ratings
2
Buy
2
Hold
1
Sell
Based on 5 analysts giving stock ratings to Gossamer Bio Inc - Dist in the past 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$